Teriflunomide reduced the risk of relapse or a new MRI lesion compared with placebo at the 14 mg dose ( HR 0651 [ 95 % CI 0515-0822 ] ; p = 00003 ) and at the 7 mg dose ( 0686 [ 0540-0871 ] ; p = 00020 ) .